Metastatic Gastroesophageal Junction Adenocarcinoma Clinical Trial
Official title:
Prospective, Randomized, Single-center Phase II Clinical Study of Camrelizumab Combined With Apatinib Versus Apaitnib Alone in the Third-line Treatment of Metastatic Gastric Cancer
This is a study of Camrelizumab combined with Apatinib versus Apatinib alone in the third-line treatment of metastatic gastric cancer. Paticipants will be radomized to receive treatment of Camrelizumab combined with Apatinib or Apatinib alone. The primary study hypothesis is that the adding Camrelizumab to Apatinib can prolong the progressive-free survival of the paticipants.
Status | Not yet recruiting |
Enrollment | 68 |
Est. completion date | November 1, 2023 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Male or female patients, age = 18 years; 2. Patients with metastatic gastric cancer confirmed by histology or cytology; 3. Baseline blood routine and biochemical indicators meet the following criteria: 1) Hemoglobin = 9.0 g/dL; 2) Absolute neutrophil count (ANC) = 1,500/mm3; 3) Platelet count= 100,000/mm3; 4) Total bilirubin = 1.5 times the upper limit of normal value (ULN); 5) Alanine aminotransferase and aspartate aminotransferase = 2.5 ULN; 6) The international standardized ratio of prothrombin time is = 1.5, and part of the thromboplastin time is within the normal range (the lower limit of 1.2 times normal value to the upper limit of 1.2 times normal value); 7) Creatinine = 1.5 ULN; 8) Urine protein <2+ (if urine protein = 2+, then 24h urine protein quantitative protein must be = 1g); 4.The presence of measurable lesions in patients; evaluated by investigators according to the Efficacy Evaluation Criteria (RECIST) v1.1 of Solid Tumors; 5.Eastern Tumor Collaboration Group Behavioral Status Score (ECOG PS) of 0 or 1; 6.Life expectancy = 3 months; 7.The investigator assessed that the patient was able to comply with the protocol requirements; 8.Capable to sign the informed consent document. Exclusion Criteria: 1. Patients who have undergone systemic chemotherapy, radiation therapy, surgery, hormone therapy or immunotherapy in the 2 weeks prior to the screening; 2. Patients with a history of taking apatinib; 3. Patients with hypertension that is difficult to control despite having been treated with multiple antihypertensive drugs (systolic blood pressure = 160 mmHg and diastolic blood pressure = 90 mmHg); 4. Patients with acute coronary syndrome (including myocardial infarction and unstable angina) within 6 months prior to admission and a history of coronary angioplasty or stenting; 5. Patients with large pleural effusions or ascites requiring drainage; 6. According to NCI-CTCAE version 5.0, patients with =grade 3 active infections; 7. Patients with symptomatic brain metastases; 8. Patients with partial or complete gastrointestinal obstruction; 9. Patients with interstitial lung disease with symptoms or signs of activity; 10. Patients with allergies or hypersensitivity to therapeutic drugs, patients with autoimmune diseases, and have received allogeneic tissue/solid organ transplants; 11. Patients requiring systemic corticosteroids (excluding temporary use for trials, prophylactic administration for anaphylactic reactions or to reduce swelling associated with radiotherapy) or immunosuppressants, or patients who had received such therapy less than 14 days prior to admission to this study; 12. Patients with seizures who require medication; 13. Patients who undergo major surgery (open chest surgery or laparotomy, etc.), laparotomy biopsy, trauma within 28 days before registration. Registration can be carried out on the same day of the week preceding 4 weeks (however, if an artificial anastomosis is performed without bowel resection, it should be within 14 days prior to registration); 14. Patients with unhealed wounds, unhealed ulcers or unhealed fractures; 15. Patients with a history of allergies to any of the drugs studied, similar drugs or excipients; 16. Simultaneous reception of any other anti-tumor therapy, including anti-tumor proprietary Chinese medicines and immunochemicals; 17. Pregnant, lactating women, fertile but refusing to use contraception; 18. Other situations in which the investigators determined that they were not suitable for inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
China | The Sixth Affiliated hosipital, Sun Yat-Sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sixth Affiliated Hospital, Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free survival | the interval from randomization to tumor progression or death or the last follow-up | 1 year | |
Secondary | Overall Survival | the interval from randomization to death of any reason or the last follow-up | 2 years | |
Secondary | Objective response rate | the proportion of subjects who achieve a best response of complete response (CR) or partial response (PR) using the RECIST 1.1 criteria | 2 years | |
Secondary | Quality of Life assessed by EORTC QLQ-OG 25 | The Europe Organization for Research and Treatment of Cancer,Quality of Life Questionnaire-OG 25 can assess quality of life (HRQL) in patients with tumours of the oesophagus, oesophago-gastric junction and stomach. | 2 years | |
Secondary | Toxicity assessed by CTCAE V5.0 | Adverse effects recorded according to CTCAE V5.0 | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01142388 -
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03337087 -
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03641313 -
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
Recruiting |
NCT04781686 -
Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05651594 -
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04511039 -
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04921904 -
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
|
Phase 1/Phase 2 | |
Recruiting |
NCT04660760 -
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05555251 -
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04840264 -
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
|
Phase 2 | |
Recruiting |
NCT06203600 -
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05677490 -
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
|
Phase 3 | |
Completed |
NCT02391038 -
MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C
|
Phase 1/Phase 2 | |
Completed |
NCT03395847 -
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
|
Early Phase 1 | |
Active, not recruiting |
NCT03008278 -
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
|
Phase 1/Phase 2 | |
Recruiting |
NCT06329973 -
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05041153 -
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
|
Early Phase 1 | |
Recruiting |
NCT04007744 -
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
|
Phase 1 |